Trial Outcomes & Findings for Perioperative Pain Management In Spine Surgery Patients: Part I (NCT NCT01447888)

NCT ID: NCT01447888

Last Updated: 2020-04-27

Results Overview

We will be assessing if the intervention improves immediate (4 hours) postoperative pain control as compared to the non-intervention group. Measures that will be used to assess immediate post-operative pain include: Verbal pain scores, opioid consumption, and vital signs. Verbal pain scores were reported using the Wong-Baker FACES pain rating scale which ranges from 0 (no hurt) to 10 (hurts worst). Higher numerical scores on the scale indicate more pain, thus a worse outcome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

100 participants

Primary outcome timeframe

4 hours post surgery

Results posted on

2020-04-27

Participant Flow

Participant milestones

Participant milestones
Measure
150% Oral Morphine Equivalent (OME)
Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients 150% Oral Morphine Equivalent (OME): Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Control
Standard perioperative dosing, which does not currently account for patients' baseline opiate use. Clinical Judgment: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Overall Study
STARTED
45
55
Overall Study
COMPLETED
45
55
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
150% Oral Morphine Equivalent (OME)
n=45 Participants
Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients 150% Oral Morphine Equivalent (OME): Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Control
n=55 Participants
Standard perioperative dosing, which does not currently account for patients' baseline opiate use. Clinical Judgment: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Total
n=100 Participants
Total of all reporting groups
Age, Continuous
51 years
STANDARD_DEVIATION 11.7 • n=45 Participants
52 years
STANDARD_DEVIATION 12.6 • n=55 Participants
51.55 years
STANDARD_DEVIATION 12.15 • n=100 Participants
Sex: Female, Male
Female
15 Participants
n=45 Participants
32 Participants
n=55 Participants
47 Participants
n=100 Participants
Sex: Female, Male
Male
30 Participants
n=45 Participants
23 Participants
n=55 Participants
53 Participants
n=100 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
45 participants
n=45 Participants
55 participants
n=55 Participants
100 participants
n=100 Participants

PRIMARY outcome

Timeframe: 4 hours post surgery

We will be assessing if the intervention improves immediate (4 hours) postoperative pain control as compared to the non-intervention group. Measures that will be used to assess immediate post-operative pain include: Verbal pain scores, opioid consumption, and vital signs. Verbal pain scores were reported using the Wong-Baker FACES pain rating scale which ranges from 0 (no hurt) to 10 (hurts worst). Higher numerical scores on the scale indicate more pain, thus a worse outcome.

Outcome measures

Outcome measures
Measure
150% Oral Morphine Equivalent (OME)
n=45 Participants
Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients 150% Oral Morphine Equivalent (OME): Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Control
n=55 Participants
Standard perioperative dosing, which does not currently account for patients' baseline opiate use. Clinical Judgment: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Immediate Postoperative Pain Control
6.6 score on a scale
Standard Deviation 2.1
6.8 score on a scale
Standard Deviation 1.5

SECONDARY outcome

Timeframe: 24 hours after the recovery period

We will be assessing if the intervention improved postoperative pain management during the first 24 hours after the recovery period (first 4 hours postoperatively) as compared to the non-intervention group. Measures that will be used to assess success: Verbal pain scores, opioid consumption (doses and frequency), and vital signs. Verbal pain scores were reported using the Wong-Baker FACES pain rating scale which ranges from 0 (no hurt) to 10 (hurts worst). Higher numerical scores on the scale indicate more pain, thus a worse outcome.

Outcome measures

Outcome measures
Measure
150% Oral Morphine Equivalent (OME)
n=45 Participants
Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients 150% Oral Morphine Equivalent (OME): Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Control
n=55 Participants
Standard perioperative dosing, which does not currently account for patients' baseline opiate use. Clinical Judgment: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Pain Management Improvement at 24 Hours After the Recovery Period
5.8 score on a scale
Standard Deviation 2.0
6.4 score on a scale
Standard Deviation 1.6

Adverse Events

150% Oral Morphine Equivalent (OME)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

John Mrachek, MD

Allina Health

Phone: 612-871-7639

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place